Updated recommendation supports universal hepatitis B vaccination for US adults aged 19-59 years

This is a recommendation report, not a research study, from the United States addressing hepatitis B vaccination in adults aged 19-59 years. The report updates prior guidance to recommend universal vaccination for this age group. No study design, sample size, comparator, or follow-up duration is reported.

No primary or secondary outcomes, effect sizes, or numerical results are presented, as this is a guidance document rather than a trial or observational study. Safety and tolerability data, including adverse events and discontinuation rates, are not reported. The report does not include information on funding or potential conflicts of interest.

Key limitations include the absence of supporting clinical data or evidence review within this report. The practice relevance is that this represents an updated public health recommendation. Clinicians should refer to the complete recommendation document, which may cite underlying evidence, for detailed implementation guidance, patient selection, and schedule information.